PMID- 22490235
OWN - NLM
STAT- MEDLINE
DCOM- 20121009
LR  - 20120607
IS  - 1532-4311 (Electronic)
IS  - 0882-0139 (Linking)
VI  - 41
IP  - 5
DP  - 2012
TI  - Human dendritic cells engineered to secrete interleukin-18 activate 
      MAGE-A3-specific cytotoxic T lymphocytes in vitro.
PG  - 469-83
LID - 10.3109/08820139.2012.664225 [doi]
AB  - Adoptive cell transfer (ACT) involves the administration of tumor specific 
      cytotoxic T lymphocytes (CTLs) into a patient to kill cancer cells. Although a 
      promising cancer therapy, limitations on the generation of activated CTLs have 
      restricted ATC's clinical application. Interleukin-18 (IL-18) is an interferon-gamma 
      (IFN-gamma) inducing factor that plays an important functional role in regulating 
      CTLs. Here, we attempt to use dendritic cells (DCs) modified with a recombinant 
      adenovirus encoding IL-18 (rAd/IL-18) to improve the generation of activated 
      tumor-specific CTLs. These engineered DCs secrete IL-18, increase the expression 
      of co-stimulatory molecules, and enhance the cytotoxic efficacy of melanoma 
      antigen 3 (MAGE-A3)-specific CTLs in vitro. We show that stimulation of CTLs with 
      rAd/IL-18-loaded DCs increases the specific lysis of MAGE-A3-expressing human 
      breast cancer MCF-7 cells, and at the same time increases the production of 
      activated MAGE-A3-specific CTLs. Our results indicate that transducing DCs with 
      rAd/IL-18 increases both the maturation of DCs and the activation level of 
      MAGE-A3-specific CTLs, greatly enhancing the cytotoxic efficacy of CTLs towards 
      tumor cells.
FAU - Fan, Xueling
AU  - Fan X
AD  - Division of Life Science, The Hong Kong University of Science and Technology, 
      Clear Water Bay, Kowloon, Hong Kong, China.
FAU - Ye, Mulin
AU  - Ye M
FAU - Xue, Bofu
AU  - Xue B
FAU - Ke, Yan
AU  - Ke Y
FAU - Wong, Chung Kai
AU  - Wong CK
FAU - Xie, Yong
AU  - Xie Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120410
PL  - England
TA  - Immunol Invest
JT  - Immunological investigations
JID - 8504629
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Interleukin-18)
RN  - 0 (MAGEA3 protein, human)
RN  - 0 (Neoplasm Proteins)
SB  - IM
MH  - Adenoviridae/genetics
MH  - Adoptive Transfer
MH  - Antigens, Neoplasm/*immunology
MH  - Cell Differentiation
MH  - Cell Line, Tumor
MH  - Dendritic Cells/cytology/*immunology
MH  - Humans
MH  - Interleukin-18/*immunology
MH  - Jurkat Cells
MH  - Neoplasm Proteins/*immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
EDAT- 2012/04/12 06:00
MHDA- 2012/10/10 06:00
CRDT- 2012/04/12 06:00
PHST- 2012/04/12 06:00 [entrez]
PHST- 2012/04/12 06:00 [pubmed]
PHST- 2012/10/10 06:00 [medline]
AID - 10.3109/08820139.2012.664225 [doi]
PST - ppublish
SO  - Immunol Invest. 2012;41(5):469-83. doi: 10.3109/08820139.2012.664225. Epub 2012 
      Apr 10.